Skip to main navigation
Skip to search
Skip to main content
Maastricht University Home
Support & FAQ
Home
Researchers
Publications
Activities
Press/Media
Prizes
Organisations
Dataset/Software
Projects
Search by expertise, name or affiliation
Nivolumab exposure in a hemodialysis patient with metastatic melanoma
Judith L Gulikers
,
Sander Croes
, Marco J W Schreurs
,
Elisabeth J R Litjens
,
Maureen J B Aarts
,
Robin M J M van Geel
*
*
Corresponding author for this work
Carim - Vascular complications of diabetes and metabolic syndrome
Clinical Pharmacy
DA KFT Medische Staf
MA Nefrologie
Interne Geneeskunde
MA Medische Oncologie
GROW - Innovative Cancer Diagnostics & Therapy
Research output
:
Contribution to journal
›
Article
›
Academic
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Nivolumab exposure in a hemodialysis patient with metastatic melanoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Hemodialysis Patients
100%
Metastatic Melanoma
100%
Nivolumab
100%
Intermittent Hemodialysis
50%
Serum Concentration
25%
Older Patients
12%
Two-sample
12%
End-stage Renal Disease
12%
Hemodialysis
12%
Renal Insufficiency
12%
Severe Renal Impairment
12%
Serum Trough Concentration
12%
INIS
patients
100%
metastases
100%
melanomas
100%
kidneys
60%
concentration
60%
diseases
20%
range
20%
Pharmacology, Toxicology and Pharmaceutical Science
Hemodialysis
100%
Metastatic Melanoma
100%
Nivolumab
100%
Kidney Failure
12%
End Stage Renal Disease
12%
Severe Renal Impairment
12%
Medicine and Dentistry
Hemodialysis
100%
Metastatic Melanoma
100%
Nivolumab
100%
End Stage Renal Disease
12%
Renal Failure
12%
Severe Renal Impairment
12%
Immunology and Microbiology
Hemodialysis
100%
Nivolumab
100%
Blood Level
25%
Trough Concentration
12%